A Cognitive-Behavioral Model of Apathy in Parkinson's Disease.

IF 2.1 4区 医学 Q3 CLINICAL NEUROLOGY Parkinson's Disease Pub Date : 2024-08-31 eCollection Date: 2024-01-01 DOI:10.1155/2024/2820257
Olivia Plant, Annika Kienast, Daniel S Drew, Elitsa D Slavkova, Kinan Muhammed, Helen Kennerley, Masud Husain
{"title":"A Cognitive-Behavioral Model of Apathy in Parkinson's Disease.","authors":"Olivia Plant, Annika Kienast, Daniel S Drew, Elitsa D Slavkova, Kinan Muhammed, Helen Kennerley, Masud Husain","doi":"10.1155/2024/2820257","DOIUrl":null,"url":null,"abstract":"<p><p>Apathy is recognized to be a common, disabling syndrome that occurs across a range of psychiatric and neurological conditions, including Parkinson's disease. It can have a significant impact on quality of life, both for people affected and those around them. Currently, there are no established, evidence-based treatments for this debilitating syndrome. Assessment and treatment have been complicated by overlaps with depression and anhedonia, as well as a lack of understanding of the underlying mechanisms. Emerging lines of evidence conceptualize apathy as a reduction of motivation associated with disordered effort-based decision-making and dysfunction of distinct neural circuitry between the basal ganglia and medial prefrontal cortex. Here, we introduce a novel cognitive-behavioral framework that can inform a clinician's conceptualization and treatment of apathy, using cognitive-behavioral therapy (CBT) techniques. We focus on people with Parkinson's disease in our model, but our approach is transdiagnostic and can be applied to other conditions. It considers both individual targets for therapy as well as maintenance and intervention at a systemic level. The generalizability and parsimony of the framework provides a structured assessment and formulation of apathy, while also allowing clinicians to remain sensitive to other neuropsychiatric symptoms that can occur alongside apathy, such as depression and anxiety.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380718/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Parkinson's Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2024/2820257","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Apathy is recognized to be a common, disabling syndrome that occurs across a range of psychiatric and neurological conditions, including Parkinson's disease. It can have a significant impact on quality of life, both for people affected and those around them. Currently, there are no established, evidence-based treatments for this debilitating syndrome. Assessment and treatment have been complicated by overlaps with depression and anhedonia, as well as a lack of understanding of the underlying mechanisms. Emerging lines of evidence conceptualize apathy as a reduction of motivation associated with disordered effort-based decision-making and dysfunction of distinct neural circuitry between the basal ganglia and medial prefrontal cortex. Here, we introduce a novel cognitive-behavioral framework that can inform a clinician's conceptualization and treatment of apathy, using cognitive-behavioral therapy (CBT) techniques. We focus on people with Parkinson's disease in our model, but our approach is transdiagnostic and can be applied to other conditions. It considers both individual targets for therapy as well as maintenance and intervention at a systemic level. The generalizability and parsimony of the framework provides a structured assessment and formulation of apathy, while also allowing clinicians to remain sensitive to other neuropsychiatric symptoms that can occur alongside apathy, such as depression and anxiety.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
帕金森病患者冷漠的认知行为模型
冷漠被认为是一种常见的致残综合征,可发生在包括帕金森病在内的一系列精神和神经疾病中。它会严重影响患者及其周围人的生活质量。目前,对于这种使人衰弱的综合症还没有成熟的循证治疗方法。由于与抑郁症和失神症的重叠,以及对其潜在机制缺乏了解,评估和治疗变得更加复杂。新出现的证据将冷漠概念化为动机的降低,这与基于努力的决策紊乱以及基底神经节和内侧前额叶皮层之间不同神经回路的功能障碍有关。在此,我们介绍一种新的认知行为框架,它可以为临床医生使用认知行为疗法(CBT)技术对冷漠进行概念化和治疗提供参考。我们的模型侧重于帕金森病患者,但我们的方法是跨诊断性的,可适用于其他疾病。它既考虑了治疗的个体目标,也考虑了系统层面的维持和干预。该框架的普适性和简约性为冷漠症提供了结构化的评估和治疗方案,同时也允许临床医生对与冷漠症同时出现的其他神经精神症状(如抑郁和焦虑)保持敏感。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Parkinson's Disease
Parkinson's Disease CLINICAL NEUROLOGY-
CiteScore
5.80
自引率
3.10%
发文量
0
审稿时长
18 weeks
期刊介绍: Parkinson’s Disease is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to the epidemiology, etiology, pathogenesis, genetics, cellular, molecular and neurophysiology, as well as the diagnosis and treatment of Parkinson’s disease.
期刊最新文献
A Cognitive-Behavioral Model of Apathy in Parkinson's Disease. Possible Implications of Managing Alexithymia on Quality of Life in Parkinson's Disease: A Systematic Review. Implications of Convolutional Neural Network for Brain MRI Image Classification to Identify Alzheimer's Disease. Potential Neuroprotective Effect of the Endocannabinoid System on Parkinson's Disease. China's Modified Version of Sniffin' Sticks 12-Identification Test Used in Chinese Parkinson's Disease and Multiple System Patients: Comparison of Three Olfactory Testing Methods.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1